Search Results
10
Everything
Search Filters
Organization
Beyond Air™
Beyond Air Announces Agreements Expanding Global Distribution of LungFit® PH
March 11, 2025 07:30 ET
|
Beyond Air™
Distribution agreements recently signed for France, Turkey, Romania and Morocco LungFit PH international distribution network now includes 18 countries Initial international orders for LungFit PH...
Beyond Air to Participate in Two Upcoming Healthcare Investor Conferences
March 06, 2025 16:05 ET
|
Beyond Air™
GARDEN CITY, N.Y., March 06, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on...
Beyond Air® Reports Fiscal Third Quarter 2025 Financial Results and Provides Corporate Update
February 10, 2025 16:05 ET
|
Beyond Air™
Revenues increased 34% compared to the previous quarter ended September 30, 2024; and exceeded $1 million Received CE Mark for LungFit PH® in Europe and Market Authorization in Australia;...
Beyond Air® Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement
February 05, 2025 09:29 ET
|
Beyond Air™
GARDEN CITY, N.Y., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on...
Beyond Air® Schedules Third Fiscal Quarter 2025 Financial Results Conference Call and Webcast
January 27, 2025 16:05 ET
|
Beyond Air™
GARDEN CITY, N.Y., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on...
Beyond Air® Announces LungFit® PH Receives Market Authorization in Australia
January 24, 2025 09:15 ET
|
Beyond Air™
GARDEN CITY, N.Y., Jan. 24, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on...
Beyond Air to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025
January 06, 2025 08:00 ET
|
Beyond Air™
GARDEN CITY, N.Y., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on...
Beyond Cancer Announces Approval by the Israeli Ministry of Health to Conduct a Phase 1b Clinical Trial Utilizing Low Volume Ultra-High Concentration Nitric Oxide (LV UNO) in Combination with Anti-PD-1 Therapy
December 03, 2024 16:05 ET
|
Beyond Air™
The Phase 1b study will evaluate LV UNO in unresectable cutaneous or subcutaneous histologically confirmed primary or metastatic solid tumor cancer patients that have progressed or have prolonged...
Beyond Air Receives CE Mark in Europe for the LungFit® PH System
December 02, 2024 07:30 ET
|
Beyond Air™
Indication covers newborn infants with hypoxic respiratory failure and peri- and post-operative pulmonary hypertension to improve right ventricular function in conjunction with heart surgery A $1...
NeuroNOS Appoints Nobel Laureate, Roger D. Kornberg, to Scientific Advisory Board
November 26, 2024 07:30 ET
|
Beyond Air™
DUBLIN and GARDEN CITY, N.Y., Nov. 26, 2024 (GLOBE NEWSWIRE) -- NeuroNOS, a pioneering biopharmaceutical company focused on developing transformative treatments for Autism Spectrum Disorder (ASD)...